...
首页> 外文期刊>Archives of public health >Evaluating the neonatal BCG vaccination programme in Ireland
【24h】

Evaluating the neonatal BCG vaccination programme in Ireland

机译:评估爱尔兰的新生儿BCG疫苗接种计划

获取原文
           

摘要

BackgroundThe aim of this study was to compare the cost effectiveness of the current Irish programme of universal BCG vaccination of infants versus a programme which considered selectively vaccinating high risk infants using decision analytical modelling. MethodsThe efficacy of the BCG vaccine was re-evaluated to inform a decision analytical model constructed to follow a birth cohort of vaccinated and unvaccinated infants over a 15?year time horizon. The number of life years gained (LYG) was the primary outcome measure and this was compared to the net cost of the vaccination strategies. ResultsIn the base case analysis, the incremental cost effectiveness ratios (ICERs) for the universal strategy and selective strategy vs no vaccination were €204,373/LYG and €143,233/LYG respectively. When comparing the incremental difference in moving from the universal to the selective strategy, the selective strategy costs €1,055,692 less per 4.8 life years lost per birth cohort. One way sensitivity analyses highlighted that a move from the universal to the selective strategy was particularly sensitive to the estimate of vaccine efficacy against deaths, the cost of administering the vaccine and the multiplier used to apportion risk of contracting tuberculosis. Probabilistic analysis suggested that a move from a universal based strategy to a selective based strategy could be deemed cost effective (probability of cost effectiveness is 76.8?%). ConclusionThe results of the study support the protective effect of the BCG vaccine in infants and quantified the cost effectiveness of the current BCG vaccination strategy and the decremental difference in moving to a selective strategy. This analysis highlights that the additional protection offered by the universal vaccination strategy is small compared to that of the selective strategy. Consideration should therefore be given to the implementation of a selective vaccination strategy, and diverting resources to improve TB case management and control.
机译:背景技术本研究的目的是比较当前爱尔兰的婴儿常规BCG疫苗接种计划与考虑使用决策分析模型选择性接种高危婴儿疫苗的计划的成本效益。方法重新评估了卡介苗的功效,以为决策分析模型提供依据,该模型可在15年的时间范围内追踪已接种疫苗和未接种疫苗的婴儿的出生队列。获得的生命年数(LYG)是主要的结局指标,并将其与疫苗接种策略的净成本进行比较。结果在基本案例分析中,通用策略和选择性策略与未接种疫苗的成本效益比(ICER)分别为204,373欧元/ LYG和143,233欧元/ LYG。当比较从普遍策略转向选择策略的增量差异时,选择策略的成本降低了,每出生4.8个生命年,就减少了1,055,692欧元。敏感性分析的一种方法强调指出,从通用策略转向选择性策略对估计针对死亡的疫苗效力,接种疫苗的成本以及用于分担感染结核病风险的乘数的估计特别敏感。概率分析表明,从普遍策略到选择性策略的转换可以认为具有成本效益(成本效益的概率为76.8%)。结论:研究结果支持了卡介苗疫苗对婴儿的保护作用,并量化了当前卡介苗疫苗接种策略的成本效益和选择策略的递减差异。该分析强调,与选择性策略相比,通用疫苗接种策略提供的额外保护很小。因此,应考虑实施选择性疫苗接种策略,并转移资源以改善结核病病例的管理和控制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号